Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Hiromitsu Takemori"'
Autor:
Kaori Kitamura, Hiroshi Shionoya, Suguru Suzuki, Richio Fukai, Shinichi Uda, Chiyuki Abe, Hiromitsu Takemori, Keita Nishimura, Hisashi Baba, Kou Katayama, Kuniaki Terato, Takaki Waritani
Publikováno v:
Journal of Immunology Research, Vol 2022 (2022)
Intestinal bacterial compositions of rheumatoid arthritis (RA) patients have been reported to be different from those of healthy people. Dysbiosis, imbalance of the microbiota, is widely known to cause gut barrier damage, resulting in an influx of ba
Externí odkaz:
https://doaj.org/article/982d4898c71945178affb9b05f46e272
Autor:
Masayuki Miyata, Yasuhiko Hirabayashi, Yasuhiko Munakata, Yukitomo Urata, Koichi Saito, Hiroshi Okuno, Masaaki Yoshida, Takao Kodera, Ryu Watanabe, Seiya Miyamoto, Tomonori Ishii, Shigeshi Nakazawa, Hiromitsu Takemori, Takanobu Ando, Takashi Kanno, Masataka Komagamine, Ichiro Kato, Yuichi Takahashi, Atsushi Komatsuda, Kojiro Endo
Publikováno v:
Fukushima Journal of Medical Science; 2023, Vol. 69 Issue 1, p11-20, 10p
Autor:
Kaori Kitamura, Hiroshi Shionoya, Suguru Suzuki, Richio Fukai, Shinichi Uda, Chiyuki Abe, Hiromitsu Takemori, Keita Nishimura, Hisashi Baba, Kou Katayama, Kuniaki Terato, Takaki Waritani
Publikováno v:
Journal of immunology research. 2022
Intestinal bacterial compositions of rheumatoid arthritis (RA) patients have been reported to be different from those of healthy people. Dysbiosis, imbalance of the microbiota, is widely known to cause gut barrier damage, resulting in an influx of ba
Autor:
Kazuhide Tanimura, Tatsuya Atsumi, Yoko Suzuki, Akito Tsutsumi, Masaru Kato, Takumi Matsumoto, Yujiro Kon, Tomonori Ishii, Tomomasa Izumiyama, Yoshiharu Amasaki, Hiroshi Kanazawa, Hideki Kasahara, Satoshi Jodo, Yuichiro Fujieda, Shinsuke Yasuda, Takashi Kurita, Michio Minami, Hiromitsu Takemori, Naofumi Yamauchi, Tamotsu Kamishima, Takao Koike, Kazumasa Ohmura
Publikováno v:
Modern Rheumatology. 27:930-937
Objectives: To preliminarily evaluate the feasibility of maintenance therapy with reduced dose of intravenous abatacept (ABT) to 250 mg/body/month after achieving remission or low disease activity (LDA). Patients and methods: RA patients treated with
Autor:
Akira Hatakeyama, Hiroko Kobayashi, Yu Mori, Seiya Miyamoto, Kenichi Asakura, Masaaki Yoshida, Hiroshi Okuno, Yasuhiko Hirabayashi, Yasuhiko Munakata, Keiki Miura, Masayuki Miyata, Ken Ogura, Masataka Komagamine, Shigeshi Nakazawa, Takao Kodera, Takao Miura, Yuya Takakubo, Kojiro Endo, Hiroshi Kanazawa, Satoshi Takasaki, Yukitomo Urata, Atsushi Komatsuda, Takashi Kanno, Hirotake Sakuraba, Ichiro Kato, Yoko Suzuki, Koichi Saito, Tomonori Ishii, Kota Sugisaki, Hiroshi Watanabe, Noriyuki Chiba, Yukio Sato, Michiaki Takagi, Takanobu Ando, Kazunobu Ichikawa, Hiromitsu Takemori, Eiji Suzuki, Tai Muryoi, Takahiro Nakayama, Hiroshi Fujii, Tomoyuki Asano, Chihiro Murai, Yuichi Takahashi, Tsuneo Konta, Yukio Sekiguchi, Ryu Watanabe
Publikováno v:
Modern Rheumatology. 26:828-835
To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA).In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy w
Autor:
Hiroshi Shionoya, R. Fukai, Chiyuki Abe, Takaki Waritani, Kou Katayama, Suguru Suzuki, Hisashi Baba, Hiromitsu Takemori, Shinichi Uda, Kuniaki Terato, Keita Nishimura, Kaori Kitamura
Publikováno v:
Annals of the Rheumatic Diseases. 81:e71-e71
The recent paper from Kishikawa et al 1 provides an extremely important new insight on the concept of oral-gut microbiome axis and rheumatoid arthritis (RA) pathogenesis. Alterations in the gut microbiome at mucosal sites have been implicated in the
Autor:
Kaori Kitamura, Hiroshi Shionoya, Kuniaki Terato, Suguru Suzuki, Richio Fukai, Shinichi Uda, Chiyuki Abe, Hiromitsu Takemori, Keita Nishimura, Hisashi Baba, Takaki Waritani, Kou Katayama, Kitamura, Kaori, Shionoya, Hiroshi, Terato, Kuniaki, Suzuki, Suguru, Fukai, Richio, Uda, Shinichi, Abe, Chiyuki, Takemori, Hiromitsu
Publikováno v:
Annals of the Rheumatic Diseases; May2022, Vol. 81 Issue 5, p1-3, 3p
Autor:
Noriyuki Chiba, Yuhji Murata, Yoshiyuki Abe, Michiaki Takagi, Takashi Kanno, Hideo Harigae, Hiromasa Ohira, Tomonori Ishii, Yukari Ninomiya, Masayuki Miyata, Atsushi Komatsuda, Yoshito Oguchi, Katsumi Chiba, Tomomasa Izumiyama, Yoshihiro Saito, Hiromitsu Takemori, Yasuhiko Hirabayashi, Ryu Watanabe, Tomoe Nishimaki, Osamu Kawamura, Hiroko Kobayashi, Yukitomo Urata, Tsuneo Konta, Takeshi Sasaki, Ichizo Asahina
Publikováno v:
The Tohoku Journal of Experimental Medicine. 233:129-133
Hepatitis B virus (HBV) reactivation has been increasingly recognized in patients receiving chemotherapy and immunosuppressive therapy; however, the prevalence of HBV infection and rate of HBV screening in patients with rheumatic diseases remains unc
Publikováno v:
The Tohoku Journal of Experimental Medicine. 170:197-205
KUROE, K., YOSHIHARA, A., AKIYAMA, M., TAKEMORI, H., and YOSHIDA, Y. The Growth of Mouse Hybridoma Cells between Peyer's Patch Lymphocyte and Myeloma Cell in the Gastrointestinal Tract. A model for Human Multiple Lymphomatous Polyposis of the Gastroi
Autor:
Naoko Sugimoto, Tsushima K, Yutaka Yoshida, Soh Saitoh, Yoshihiro Tamura, Hidekazu Suzuki, Hiromitsu Takemori, Yuh Sakata, Tohru Itoh, Ogasawara H
Publikováno v:
Cancer Immunology Immunotherapy. 32:88-94
We have previously reported that the combination of murine recombinant interferon beta (Mu-rIFN beta) with murine recombinant interferon gamma (Mu-rIFN gamma) provided greater inhibition of tumor growth than did each one alone in MethA-bearing mice.